Inaugural program provides unprecedented access to Tempus’ library of de-identified multimodal data and models, scalable compute infrastructure and direct funding to catalyze clinical and technical breakthroughs

CHICAGO: Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine, today announced the launch of the PRECISION Challenge, a national initiative engineered to accelerate the next generation of oncology breakthroughs leveraging its foundational model. The PRECISION Challenge aims to unlock breakthroughs in oncology at scale by providing access to data, funding, and expertise to multidisciplinary teams around the world who seek to make bold advances in cancer treatment and improve patient outcomes.

The PRECISION Challenge will provide selected participants with an unprecedented ecosystem of resources, combining direct financial funding with scientific and analytical infrastructure. Program recipients will gain structured access to Tempus’ proprietary, de-identified data library-one of the world's largest repositories of clinical, molecular, and imaging data-alongside a suite of Tempus’ foundation models, agentic tooling, and compute infrastructure in the Lens Workspaces environment, designed to accelerate biological discovery from multimodal real world data.

As part of the PRECISION Challenge, Tempus and a group of external advisors will identify specific clinical and technical challenges for the research community to address, focused on advancing precision medicine in oncology by leveraging Tempus’ large multimodal foundation model.

The program will provide staged funding and compute resources tied to research milestones and demonstrated progress:

• Proof of Concept Grant: $25,000 in funding and an allocation for compute to support early-stage development and feasibility testing.
• “Level-Up” Grant: $75,000 in funding and an allocation for compute to support more advanced development, such as demonstrating clinical performance, achieving model lock, or validating reproducibility.
• Additional rounds of funding and advanced computing resources will be available to further advance selected projects, including support for validation studies and external publication.

"Oncology research is no longer bottlenecked solely by scientific hypotheses, but by immediate access to high-fidelity data and the massive computational power required to interpret it," said Ezra Cohen, MD, and Chief Medical Officer of Oncology at Tempus. "With the PRECISION Challenge, we are opening Tempus capabilities and allowing the broader research community to access the vast investments we have made in building our foundation model. We will embark on this effort collaboratively to address the fundamental questions in oncology that, before now, were impossible to address."

Tempus will announce the opening of applications for the inaugural cohort of the PRECISION Challenge in the coming months. Researchers and investigators are encouraged to apply.

About Tempus

Tempus is a technology company advancing precision medicine through the practical application of artificial intelligence in healthcare. With one of the world’s largest libraries of multimodal data, and an operating system to make that data accessible and useful, Tempus provides AI-enabled precision medicine solutions to physicians to deliver personalized patient care and in parallel facilitates discovery, development and delivery of optimal therapeutics. The goal is for each patient to benefit from the treatment of others who came before by providing physicians with tools that learn as the company gathers more data. For more information, visit tempus.com.

Forward Looking Statements

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended (the “Securities Act”), and Section 21E of the Securities Exchange Act of 1934, as amended, about Tempus and Tempus’ industry that involve substantial risks and uncertainties. All statements other than statements of historical facts contained in this press release are forward-looking statements, including, but not limited to, statements regarding expected outcomes and benefits of Tempus’ PRECISION Challenge. In some cases, you can identify forward-looking statements because they contain words such as “anticipate,” “believe,” “contemplate,” “continue,” “could,” “estimate,” “expect,” “going to,” “intend,” “may,” “plan,” “potential,” “predict,” “project,” “should,” “target,” “will,” or “would” or the negative of these words or other similar terms or expressions. Tempus cautions you that the foregoing may not include all of the forward-looking statements made in this press release.

You should not rely on forward-looking statements as predictions of future events. Tempus has based the forward-looking statements contained in this press release primarily on its current expectations and projections about future events and trends that it believes may affect Tempus’ business, financial condition, results of operations and prospects. These forward-looking statements are subject to risks and uncertainties related to: the intended use of Tempus’ products and services; Tempus’ financial performance; the ability to attract and retain customers and partners; managing Tempus’ growth and future expenses; competition and new market entrants; compliance with new laws, regulations and executive actions, including any evolving regulations in the artificial intelligence space; the ability to maintain, protect and enhance Tempus’ intellectual property; the ability to attract and retain qualified team members and key personnel; the ability to repay or refinance outstanding debt, or to access additional financing; future acquisitions, divestitures or investments; the potential adverse impact of climate change, natural disasters, health epidemics, macroeconomic conditions, and war or other armed conflict, as well as risks, uncertainties, and other factors described in the section titled “Risk Factors” in Tempus’ Annual Report on Form 10-K for the year ended December 31, 2025, filed with the Securities and Exchange Commission (“SEC”) on February 24, 2026, as well as in other filings Tempus may make with the SEC in the future. In addition, any forward-looking statements contained in this press release are based on assumptions that Tempus believes to be reasonable as of this date. Tempus undertakes no obligation to update any forward-looking statements to reflect events or circumstances after the date of this press release or to reflect new information or the occurrence of unanticipated events, except as required by law.

Fonte: Business Wire